1
|
Gu C, Zhang T, Gao Y, Li X, Yuan X, Wang Q, Liu H, Han R, Li G. Lanthanum Hydroxide and Chronic Kidney Disease Mineral and Bone Disorder: A Rat Model. Curr Vasc Pharmacol 2024; 22:122-136. [PMID: 37961858 DOI: 10.2174/0115701611254269231105063028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 08/27/2023] [Accepted: 10/16/2023] [Indexed: 11/15/2023]
Abstract
OBJECTIVE To investigate the pharmacological effects and molecular mechanisms of lanthanum hydroxide(LH) on ectopic mineralization of soft tissue and abnormal bone in rats with acute kidney injury(AKI). METHODS Wistar rats were modeled by 5/6 nephrectomy. After the operation, the rats were divided into different groups, the biochemical indexes of serum collected at different times. LH was administered by intragastric tube at doses of 0.4, 0.2, and 0.1g/kg, respectively. Rats were sacrificed in the 16th week after LH treatment. Observation of pathological changes in tissues were made by specific staining. Western Blot, Real-Time Quantitative PCR, and immunohistochemistry techniques were used to detect the impact on pathway-related proteins. RESULTS Compared with the control group (no LH administered), the serum phosphate level of the LH group was significantly reduced (p<0.01), calcification of the thoracic aorta was reduced (p<0.05, p<0.01) (Serum biochemical tests before dosing and during drug treatment cycles), renal fibrosis was improved (p<0.01), nuclear entry of nuclear factor kappa-B (NF-κB) was reduced (p<0.01), and the expression of the smooth muscle protein 22α (SM22α) was significantly increased (p<0.01). The expression of osteogenic marker genes was decreased. In addition, compared with the controls, the receptor activator for nuclear factor-κB ligand/osteoprotegerin (RANKL/OPG) ratio of the femur in the model group was increased (p<0.05). CONCLUSION LH can inhibit the occurrence and development of vascular calcification and bone abnormalities in AKI rats by inhibiting the NF-κB and RANKL/OPG signaling pathways.
Collapse
Affiliation(s)
- Chao Gu
- Department of Pharmacy, Ordos City Hospital, Dongsheng District, Ordos City, 017000, Inner Mongolia Autonomous Region, China
| | - Ting Zhang
- Department of Pharmacology, College of Pharmacy, the Inner Mongolian Medical University, Jinshan Development, Hohhot, 010110, Inner Mongolia Autonomous Region, China
| | - Yuan Gao
- Department of Pharmacology, College of Pharmacy, the Inner Mongolian Medical University, Jinshan Development, Hohhot, 010110, Inner Mongolia Autonomous Region, China
| | - Xiaojia Li
- Department of Pharmacology, College of Pharmacy, the Inner Mongolian Medical University, Jinshan Development, Hohhot, 010110, Inner Mongolia Autonomous Region, China
| | - Xiaorong Yuan
- Department of Pharmacology, College of Pharmacy, the Inner Mongolian Medical University, Jinshan Development, Hohhot, 010110, Inner Mongolia Autonomous Region, China
| | - Qiwen Wang
- Department of Pharmacology, College of Pharmacy, the Inner Mongolian Medical University, Jinshan Development, Hohhot, 010110, Inner Mongolia Autonomous Region, China
| | - Hong Liu
- Department of Pharmacology, College of Pharmacy, the Inner Mongolian Medical University, Jinshan Development, Hohhot, 010110, Inner Mongolia Autonomous Region, China
| | - Ruilan Han
- Department of Pharmacology, College of Pharmacy, the Inner Mongolian Medical University, Jinshan Development, Hohhot, 010110, Inner Mongolia Autonomous Region, China
| | - Gang Li
- Department of Pharmacology, College of Pharmacy, the Inner Mongolian Medical University, Jinshan Development, Hohhot, 010110, Inner Mongolia Autonomous Region, China
| |
Collapse
|
2
|
GU C, GAO Y, HAN R, GUO M, LIU H, GAO J, LIU Y, LI B, SUN L, BU R, LIU Y, HAO J, MENG Y, AN M, CAO X, SU C, LI G. Metabolomics of clinical samples reveal the treatment mechanism of lanthanum hydroxide on vascular calcification in chronic kidney disease. PROCEEDINGS OF THE JAPAN ACADEMY. SERIES B, PHYSICAL AND BIOLOGICAL SCIENCES 2022; 98:361-377. [PMID: 35908957 PMCID: PMC9363596 DOI: 10.2183/pjab.98.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Accepted: 05/17/2022] [Indexed: 06/15/2023]
Abstract
Previous studies showed that lanthanum hydroxide (LH) has a therapeutic effect on chronic kidney disease (CKD) and vascular calcification, which suggests that it might have clinical value. However, the target and mechanism of action of LH are unclear. Metabolomics of clinical samples can be used to predict the mechanism of drug action. In this study, metabolomic profiles in patients with end-stage renal disease (ESRD) were used to screen related signaling pathways, and we verified the influence of LH on the ROS-PI3K-AKT-mTOR-HIF-1α signaling pathway by western blotting and quantitative real-time RT-qPCR in vivo and in vitro. We found that ROS and SLC16A10 genes were activated in patients with ESRD. The SLC16A10 gene is associated with six significant metabolites (L-cysteine, L-cystine, L-isoleucine, L-arginine, L-aspartic acid, and L-phenylalanine) and the PI3K-AKT signaling pathway. The results showed that LH inhibits the ESRD process and its cardiovascular complications by inhibiting the ROS-PI3K-AKT-mTOR-HIF-1α signaling pathway. Collectively, LH may be a candidate phosphorus binder for the treatment of vascular calcification in ESRD.
Collapse
Affiliation(s)
- Chao GU
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Yuan GAO
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Ruilan HAN
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Min GUO
- Department of Clinical Pharmacy, Ordos Central Hospital, Ordos City, Inner Mongolia Autonomous Region, China
| | - Hong LIU
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Jie GAO
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Yang LIU
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Bing LI
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Lijun SUN
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Ren BU
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Yang LIU
- Department of Clinical Pharmacy, Ordos Central Hospital, Ordos City, Inner Mongolia Autonomous Region, China
| | - Jian HAO
- Renal Division, The First Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Yan MENG
- Renal Division, The First Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Ming AN
- Department of Pharmaceutical analysis, School of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia Autonomous Region, China
| | - Xiaodong CAO
- Department of Pharmacology, GLP Center, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| | - Changhai SU
- Department of Clinical Pharmacy, Ordos Central Hospital, Ordos City, Inner Mongolia Autonomous Region, China
| | - Gang LI
- Department of Pharmacology, College of Pharmacy, Inner Mongolian Medical University, Hohhot, Inner Mongolia Autonomous Region, China
- Mongolian Medicine Collaborative Innovation Center, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, China
| |
Collapse
|